|
|
Rezende,A.F.S.; Brum,A.A.; Bezerra,F.S.B.; Braite,D.C.; Sá,G.L.; Thurow,H.S.; Seixas,F.K.; Azevedo,V.A.C.; Portela,R.W.; Borsuk,S.. |
ABSTRACT The target cp1002_RS01850 from Corynebacterium pseudotuberculosis was used to construct a DNA and recombinant subunit vaccine against caseous lymphadenitis. Recombinant protein rCP01850 was expressed in Escherichia coli using pAE vector, and DNA vaccine was engineered with pTARGET vector. BALB/c mice were divided in five groups containing eight animals each, inoculated with: pTARGET/cp01850 as DNA vaccine (G1); rCP01850 plus Al (OH)3 as recombinant subunit vaccine (G2); pTARGET/cp01850 and a boost with rCP01850 plus Al (OH)3 (G3); pTARGET (G4); or Al (OH)3 (G5). Mice were inoculated and blood samples were collected on days 0, 21, and 42 for the analysis of total IgG, IgG1 and IgG2a by ELISA. In each group, five animals were challenged with Mic-6... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Cp1002_RS01850 gene; Immunization; Recombinant protein; Aluminum hydroxide; Heterologous prime-boost strategy. |
Ano: 2020 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-09352020000100199 |
| |